Cargando…

Multicentric carpotarsal osteolysis syndrome (MCTO) with generalized high bone turnover and high serum RANKL: Response to denosumab

MCTO is a rare disorder, caused by mutations in the MafB gene, a negative regulator of receptor activator of nuclear factor-кB ligand (RANKL). Manifestations include carpal and tarsal osteolysis and renal failure. Pathophysiology is poorly understood, and no effective treatment is available. In this...

Descripción completa

Detalles Bibliográficos
Autores principales:	Regev, Ravit, Sochett, Etienne B., Elia, Yesmino, Laxer, Ronald M., Noone, Damien, Whitney-Mahoney, Kristi, Filipowski, Kornelia, Shamas, Amer, Vali, Reza
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7815641/ https://www.ncbi.nlm.nih.gov/pubmed/33506078 http://dx.doi.org/10.1016/j.bonr.2021.100747

Ejemplares similares

MON-LB72 Multicentric Carpotarsal Osteolysis Syndrome (MCTO) Has a Generalized High Turnover Bone Phenotype, High S RANKL and Responds to Denosumab
por: Regev, Ravit, et al.
Publicado: (2020)

Denosumab Treatment Does Not Halt Progression of Bone Lesions in Multicentric Carpotarsal Osteolysis Syndrome
por: Lerman, Melissa A., et al.
Publicado: (2023)

Three cases of multicentric carpotarsal osteolysis syndrome: a case series
por: Park, Peong Gang, et al.
Publicado: (2018)

The First Report of Multicentric Carpotarsal Osteolysis Syndrome Caused by MAFB Mutation in Asian
por: Choochuen, Pongsakorn, et al.
Publicado: (2018)

Zebrafish mafbb Mutants Display Osteoclast Over-Activation and Bone Deformity Resembling Osteolysis in MCTO Patients
por: Han, Yujie, et al.
Publicado: (2021)

A CARE-compliant article: A case report of scoliosis complicated with multicentric carpotarsal osteolysis
por: Miyazaki, Kunihiko, et al.
Publicado: (2019)

Multicentric Carpotarsal Osteolysis Syndrome Associated Nephropathy: Novel Variants of MAFB Gene and Literature Review
por: Drovandi, Stefania, et al.
Publicado: (2022)

Treatment of a young child with multicentric carpotarsal osteolysis exhibiting joint inflammation and dysfunctional bone formation
por: Trinkino, Bailey, et al.
Publicado: (2023)

Remarkable improvement of articular pain by biologics in a Multicentric carpotarsal osteolysis patient with a mutation of MAFB gene.
por: Nishikomori, R, et al.
Publicado: (2015)

Trio Clinical Exome Sequencing in a Patient With Multicentric Carpotarsal Osteolysis Syndrome: First Case Report in the Balkans
por: Stajkovska, Aleksandra, et al.
Publicado: (2018)

Mice harboring an MCTO mutation exhibit renal failure resembling nephropathy in human patients
por: Tsunakawa, Yuki, et al.
Publicado: (2018)

Targeting the tumour microenvironment: denosumab, a new RANKL inhibitor
por: Coleman, RE
Publicado: (2009)

Pros and Cons of Denosumab Treatment for Osteoporosis and Implication for RANKL Aptamer Therapy
por: Zhang, Ning, et al.
Publicado: (2020)

The Role of RANKL/RANK/OPG System in the Canine Model of Hip Periprosthetic Infection Osteolysis
por: Zhang, Hao-Wei, et al.
Publicado: (2017)

Denosumab in pediatric bone disorders and the role of RANKL blockade: a narrative review
por: Wang, Daoxi, et al.
Publicado: (2023)

Jatrorrhizine Hydrochloride Suppresses RANKL-Induced Osteoclastogenesis and Protects against Wear Particle-Induced Osteolysis
por: Li, Hui, et al.
Publicado: (2018)

Piperlongumine Inhibits Titanium Particles-Induced Osteolysis, Osteoclast Formation, and RANKL-Induced Signaling Pathways
por: Liu, Xuan, et al.
Publicado: (2022)

Denosumab for treating periprosthetic osteolysis; study protocol for a randomized, double-blind, placebo-controlled trial
por: Sköldenberg, Olof, et al.
Publicado: (2016)

Lost bones: differential diagnosis of acro-osteolysis seen by the pediatric rheumatologist
por: Limenis, Elizaveta, et al.
Publicado: (2021)

MicroRNA-106b inhibits osteoclastogenesis and osteolysis by targeting RANKL in giant cell tumor of bone
por: Wang, Ting, et al.
Publicado: (2015)

Denosumab mimics the natural decoy receptor osteoprotegerin by interacting with its major binding site on RANKL
por: Schieferdecker, Aneta, et al.
Publicado: (2014)

Denosumab Attenuates Glucolipotoxicity-Induced β-Cell Dysfunction and Apoptosis by Attenuating RANK/RANKL Signals
por: Lin, Sheng-Chieh, et al.
Publicado: (2023)

Curcumin Attenuation of Wear Particle-Induced Osteolysis via RANKL Signaling Pathway Suppression in Mouse Calvarial Model
por: Cheng, Tao, et al.
Publicado: (2017)

IL-11 is essential in promoting osteolysis in breast cancer bone metastasis via RANKL-independent activation of osteoclastogenesis
por: Liang, Mengmeng, et al.
Publicado: (2019)

Lycorine suppresses RANKL-induced osteoclastogenesis in vitro and prevents ovariectomy-induced osteoporosis and titanium particle-induced osteolysis in vivo
por: Chen, Shuai, et al.
Publicado: (2015)

Relationship between risk factors for impaired bone health and HR-pQCT in young adults with type 1 diabetes
por: Sochett, Etienne B., et al.
Publicado: (2023)

The Inhibition of RANKL-Induced Osteoclastogenesis through the Suppression of p38 Signaling Pathway by Naringenin and Attenuation of Titanium-Particle-Induced Osteolysis
por: Wang, Wengang, et al.
Publicado: (2014)

Inhibition of RANKL- induced osteoclastogenesis through the suppression of the ERK signaling pathway by astragaloside IV and attenuation of titanium- particle- induced osteolysis
Publicado: (2018)

Puerarin inhibits titanium particle‐induced osteolysis and RANKL‐induced osteoclastogenesis via suppression of the NF‐κB signaling pathway
por: Tang, Wenkai, et al.
Publicado: (2020)

Celastrol Attenuates RANKL-Induced Osteoclastogenesis in vitro and Reduces Titanium Particle-Induced Osteolysis and Ovariectomy-Induced Bone Loss in vivo
por: Xu, Qiang, et al.
Publicado: (2021)

Identifying the preferable rheumatoid arthritis subgroups for intervention with the anti-RANKL antibody denosumab to reduce progression of joint destruction
por: Tanaka, Yoshiya, et al.
Publicado: (2020)

Effect of denosumab, a human monoclonal antibody of receptor activator of nuclear factor kappa-B ligand (RANKL), upon glycemic and metabolic parameters: Effect of denosumab on glycemic parameters
por: Abe, Ichiro, et al.
Publicado: (2019)

Acro-osteolysis
por: Thomas, Joe, et al.
Publicado: (2019)

Host-derived RANKL is responsible for osteolysis in a C4-2 human prostate cancer xenograft model of experimental bone metastases
por: Morrissey, Colm, et al.
Publicado: (2007)

ER Stress Mediates TiAl(6)V(4) Particle-Induced Peri-Implant Osteolysis by Promoting RANKL Expression in Fibroblasts
por: Wang, Zhenheng, et al.
Publicado: (2015)

High bone turnover elevates the risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis
por: Ishikawa, Koji, et al.
Publicado: (2016)

BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells
por: Cuyàs, Elisabet, et al.
Publicado: (2017)

Prognostic Value and Quantitative CT Analysis in RANKL Expression of Spinal GCTB in the Denosumab Era: A Machine Learning Approach
por: Wang, Qizheng, et al.
Publicado: (2022)

20(S)-Protopanaxadiol Inhibits Titanium Particle-Induced Inflammatory Osteolysis and RANKL-Mediated Osteoclastogenesis via MAPK and NF-κB Signaling Pathways
por: Pan, Chenhao, et al.
Publicado: (2019)

Magnoflorine Suppresses MAPK and NF-κB Signaling to Prevent Inflammatory Osteolysis Induced by Titanium Particles In Vivo and Osteoclastogenesis via RANKL In Vitro
por: Sun, Zhenyu, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_o6k8mm59locn8jgb9oa5k68ogv